¼Òȱ⺴ ½ÃÀå ±Ô¸ð, Á¡À¯À², ¼ºÀå ºÐ¼® : À¯Çüº°, À¯Åë ä³Îº°, ¿ëµµº°, Åõ¿© °æ·Îº°, Áö¿ªº° - »ê¾÷ ¿¹Ãø(2025-2032³â)
Gastroenterology Market Size, Share, Growth Analysis, By Type (Branded, Generics), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies), By Application, By Route Of Administration, By Region - Industry Forecast 2025-2032
¼¼°èÀÇ ¼Òȱ⺴ ½ÃÀå ±Ô¸ð´Â 2023³â 374¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, ¿¹Ãø ±â°£(2025-2032) µ¿¾È 5.9%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î 2024³â 626¾ï 5,000¸¸ ´Þ·¯¿¡¼ 2032³â 626¾ï 5,000¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¼Òȱ⺴ ½ÃÀåÀº ½Ä½À°ü º¯È¿Í °í·É Àα¸ Áõ°¡·Î ÀÎÇÑ ¼Òȱ⺴ÀÇ À¯º´·ü Áõ°¡·Î ÀÎÇØ °ý¸ñÇÒ ¸¸ÇÑ ¼ºÀåÀ» º¸À̰í ÀÖ½À´Ï´Ù. ¼Òȱ⺴ÀÇ ±ÞÁõÀº ÀÔ¿ø ¹× ¼ö¼ú Áõ°¡·Î À̾îÁö¸ç, ÁÖ¿ä ±â¾÷Àº »ý¹°Á¦Á¦ ¹× ¹ÙÀÌ¿À½Ã¹Ð·¯ ÀǾàǰÀÇ ¿¬±¸°³¹ßÀ» °ÈÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ 2021³â 5¿ù ±âÁØ 6,443°ÇÀÇ ÀÓ»ó½ÃÇèÀÌ ÁøÇà ÁßÀ̶ó´Â ÀÓ»ó½ÃÇèÀÇ È®´ë´Â ¼¼Æ÷Ä¡·áÁ¦ ¹× ÀúºÐÀÚ ÈÇÕ¹°À» Æ÷ÇÔÇÑ Çõ½ÅÀû Ä¡·áÁ¦¸¦ À§ÇÑ °·ÂÇÑ ÆÄÀÌÇÁ¶óÀÎÀ» º¸¿©ÁÖ°í ÀÖ½À´Ï´Ù. ÇコÄɾî ȯ°æÀÇ º¯È ¼Ó¿¡¼ ÀÌ·¯ÇÑ °³¹ßÀº È¿°úÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ »õ·Î¿î ±âȸ¸¦ Á¦°øÇϰí ÇâÈÄ ¼ö³â°£ ¼Òȱ⺴ ½ÃÀåÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.
¸ñÂ÷
¼·Ð
- Á¶»çÀÇ ¸ñÀû
- Á¶»ç ¹üÀ§
- Á¤ÀÇ
Á¶»ç ¹æ¹ý
- Á¤º¸ Á¶´Þ
- 2Â÷ µ¥ÀÌÅÍ¿Í 1Â÷ µ¥ÀÌÅÍ ¹æ¹ý
- ½ÃÀå ±Ô¸ð ¿¹Ãø
- ½ÃÀåÀÇ ÀüÁ¦Á¶°Ç°ú Á¦ÇÑ
°³¿ä
- ¼¼°è ½ÃÀå Àü¸Á
- °ø±Þ°ú ¼ö¿äÀÇ µ¿Ç⠺м®
- ºÎ¹®º° ±âȸ ºÐ¼®
½ÃÀå ¿ªÇаú Àü¸Á
- ½ÃÀå °³¿ä
- ½ÃÀå ±Ô¸ð
- ½ÃÀå ¿ªÇÐ
- ÃËÁø¿äÀΰú ±âȸ
- ¾ïÁ¦¿äÀΰú °úÁ¦
- PorterÀÇ »ê¾÷ ºÐ¼®
ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ®
- ÁÖ¿ä ¼º°ø ¿äÀÎ
- °æÀïÀÇ Á¤µµ
- ÁÖ¿ä ÅõÀÚ ±âȸ
- ½ÃÀå ¿¡ÄڽýºÅÛ
- ½ÃÀåÀÇ ¸Å·Â Áö¼ö(2024³â)
- PESTEL ºÐ¼®
- °Å½Ã°æÁ¦ ÁöÇ¥
- ¹ë·ùüÀÎ ºÐ¼®
- °¡°Ý ºÐ¼®
¼Òȱ⺴ ½ÃÀå ±Ô¸ð : À¯Çüº°
¼Òȱ⺴ ½ÃÀå ±Ô¸ð : À¯Åë ä³Îº°
- ½ÃÀå °³¿ä
- ¼Ò¸Å ¾à±¹
- º´¿ø ¾à±¹
- ¿Â¶óÀÎ ¾à±¹
¼Òȱ⺴ ½ÃÀå ±Ô¸ð : ¿ëµµº°
- ½ÃÀå °³¿ä
- Å©·Ðº´
- ±Ë¾ç¼º ´ëÀå¿°
- GERD
- IBS
- ±âŸ
¼Òȱ⺴ ½ÃÀå ±Ô¸ð : Åõ¿© °æ·Îº°
- ½ÃÀå °³¿ä
- ÁÖ»ç °¡´É
- °æ±¸ ¹× ±âŸ
¼Òȱ⺴ ½ÃÀå ±Ô¸ð
- ºÏ¹Ì
- À¯·´
- µ¶ÀÏ
- ½ºÆäÀÎ
- ÇÁ¶û½º
- ¿µ±¹
- ÀÌÅ»¸®¾Æ
- ±âŸ À¯·´ Áö¿ª
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- Áß±¹
- Àεµ
- ÀϺ»
- Çѱ¹
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- ºê¶óÁú
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä« Áö¿ª
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- GCC ±¹°¡
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
°æÀï Á¤º¸
- »óÀ§ 5»çÀÇ ºñ±³
- ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Æ÷Áö¼Å´×(2024³â)
- ÁÖ¿ä ½ÃÀå ±â¾÷ÀÌ Ã¤ÅÃÇÑ Àü·«
- ½ÃÀåÀÇ ÃÖ±Ù µ¿Çâ
- ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â)
- ÁÖ¿ä ±â¾÷ÀÇ ±â¾÷ °³¿ä
- ȸ»ç °³¿ä
- Á¦Ç° Æ÷Æ®Æú¸®¿À ºÐ¼®
- ºÎ¹®º° Á¡À¯À² ºÐ¼®
- ¸ÅÃâÀÇ Àü³â´ëºñ ºñ±³(2022-2024)
ÁÖ¿ä ±â¾÷ °³¿ä
- AbbVie Inc.(US)
- Takeda Pharmaceutical Company Limited(Japan)
- AstraZeneca plc(UK)
- Bayer AG(Germany)
- Pfizer Inc.(US)
- Johnson & Johnson(US)
- Novartis AG(Switzerland)
- Merck & Co., Inc.(US)
- Sanofi S.A.(France)
- GlaxoSmithKline plc(UK)
- Boehringer Ingelheim International GmbH(Germany)
- Teva Pharmaceutical Industries Limited(Israel)
- Boston Scientific Corporation(US)
- Medtronic plc(Ireland)
- Olympus Corporation(Japan)
- Fujifilm Corporation(Japan)
- Stryker Corporation(US)
- Nestle Health Science(Switzerland)
- Danone S.A.(France)
°á·Ð°ú ±ÇÀå»çÇ×
KSA
Global Gastroenterology Market size was valued at USD 37.4 billion in 2023 and is poised to grow from USD 62.65 billion in 2024 to USD 62.65 billion by 2032, growing at a CAGR of 5.9% during the forecast period (2025-2032).
The gastroenterology market is witnessing significant growth, driven by the increasing prevalence of gastrointestinal diseases, largely attributable to poor dietary habits and a growing elderly population. The surge in gastrointestinal disorders has led to a rise in hospitalizations and surgical interventions, prompting biopharmaceutical companies to intensify their R&D efforts in biologics and biosimilars. Additionally, the expansion of clinical trials, with 6,443 ongoing studies as of May 2021, indicates a robust pipeline for innovative treatments, including cellular therapies and small compounds. As the healthcare landscape evolves, these developments present new opportunities for effective therapies, further propelling the growth of the gastroenterology market in the coming years.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Gastroenterology market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Gastroenterology Market Segmental Analysis
Global Gastroenterology Market is segmented by type, distribution channel, application, route of administration and region. Based on type, the market is segmented into branded and generics. Based on distribution channel, the market is segmented into retail pharmacies, hospital pharmacies and online pharmacies. Based on application, the market is segmented into crohn's disease, ulcerative colitis, Gerd, IBS and others. Based on route of administration, the market is segmented into injectable and oral & others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Gastroenterology Market
The global gastroenterology market is being significantly influenced by the rising incidence of gastrointestinal diseases, such as gallstones, ulcerative colitis, hemorrhoids, and irritable bowel syndrome (IBS). Factors contributing to the increasing prevalence of both chronic and acute gastrointestinal conditions include unhealthy dietary choices, sedentary lifestyles, heightened stress levels, food sensitivities, and bacterial or viral infections. Consequently, there is a growing demand for various medications, including antacids, proton pump inhibitors, histamine H2-receptor antagonists, and antibiotics, to effectively manage these disorders and prevent related health complications. This surge in healthcare needs is propelling the expansion of the global market for gastroenterology therapeutics.
Restraints in the Global Gastroenterology Market
The global gastroenterology market is expected to encounter considerable challenges during the forecast period, primarily due to the escalating costs associated with treatments. Various gastrointestinal disorders, including chronic conditions like Crohn's disease and ulcerative colitis, require ongoing management to prevent recurrence and potential complications such as cancer. The comprehensive treatment expenses encompass medication costs, consultations, and hospital admissions, which significantly contribute to the overall financial burden. For instance, biologic therapies such as infliximab and vedolizumab can range from $6,000 to $8,700 per prescription, while monthly costs for some treatments can vary between $2,500 and $5,500. These increasing out-of-pocket expenses for treatments and procedures are likely to hinder the market's growth.
Market Trends of the Global Gastroenterology Market
The global gastroenterology market is poised for significant growth, fueled by the rising prevalence of gastrointestinal disorders like ulcerative colitis and Crohn's disease. Pharmaceutical and biotechnology companies are increasingly investing in research and development to innovate cutting-edge therapies, expanding their product pipelines to meet this growing demand. This trend is marked by a strong focus on developing revolutionary treatments that promise enhanced efficacy for patients. As both regional and global players ramp up their efforts in drug development, the global therapeutics market for gastrointestinal diseases is expected to thrive, presenting substantial opportunities for stakeholders over the forecast period.
Table of Contents
Introduction
- Objectives of the Study
- Scope of the Report
- Definitions
Research Methodology
- Information Procurement
- Secondary & Primary Data Methods
- Market Size Estimation
- Market Assumptions & Limitations
Executive Summary
- Global Market Outlook
- Supply & Demand Trend Analysis
- Segmental Opportunity Analysis
Market Dynamics & Outlook
- Market Overview
- Market Size
- Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
- Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers
Key Market Insights
- Key Success Factors
- Degree of Competition
- Top Investment Pockets
- Market Ecosystem
- Market Attractiveness Index, 2024
- PESTEL Analysis
- Macro-Economic Indicators
- Value Chain Analysis
- Pricing Analysis
Global Gastroenterology Market Size by Type & CAGR (2025-2032)
- Market Overview
- Branded
- Generics
Global Gastroenterology Market Size by Distribution Channel & CAGR (2025-2032)
- Market Overview
- Retail Pharmacies
- Hospital Pharmacies
- Online Pharmacies
Global Gastroenterology Market Size by Application & CAGR (2025-2032)
- Market Overview
- Crohn's Disease
- Ulcerative Colitis
- Gerd
- IBS
- Others
Global Gastroenterology Market Size by Route Of Administration & CAGR (2025-2032)
- Market Overview
- Injectable
- Oral & Others
Global Gastroenterology Market Size & CAGR (2025-2032)
- North America (Type, Distribution Channel, Application, Route Of Administration)
- Europe (Type, Distribution Channel, Application, Route Of Administration)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Type, Distribution Channel, Application, Route Of Administration)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Type, Distribution Channel, Application, Route Of Administration)
- Brazil
- Rest of Latin America
- Middle East & Africa (Type, Distribution Channel, Application, Route Of Administration)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2024
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2024
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)
Key Company Profiles
- AbbVie Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co., Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boehringer Ingelheim International GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Teva Pharmaceutical Industries Limited (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Boston Scientific Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Medtronic plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Olympus Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Fujifilm Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Stryker Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Nestle Health Science (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Danone S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Conclusion & Recommendations